🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Alector, Inc. ALEC R2K

Healthcare · Biotechnology · United States
https://www.alector.com

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

READ MORE ›
$2.16
+62.41% 1Y

Market & Price

Market Cap
$239.81M
Current Price
$2.16
High / Low (52W)
$3.32 / $1.14
Beta
0.65

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.09
Price to Book
22.98
P/S
13.02
EV/EBITDA
-0.53
Dividend Yield
-

Profitability & Returns

ROCE
-69.73%
ROE
-
ROA
-25.71%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.21
EPS (TTM)
$-1.19

Balance Sheet & Liquidity

Debt/Equity
3.33
Quick Ratio
5.04
Current Ratio
5.25
Debt
$34.55M
Total Assets
$293.24M
Current Assets
$266.45M
Working Capital
$196.95M

Ownership

Promoter Holding
9.56%
Chg in Prom Hold
-0.00%
FII / Inst Holding
82.26%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$67.85M
Total Revenue (TTM)
$18.42M
EBITDA
$-127.49M
Free Cash Flow
$-119.11M
Operating Cash Flow
$-173.06M
Shares Outstanding
111.03M
Gross Margin
0.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-46.00%
Profit 5Y
-2.41%
Revenue (YoY)
-71.50%
Earnings (YoY)
-

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -46.0% CAGR over 5 years.
  • Earnings shrank at -2.4% CAGR over 5 years.
  • Trading 34.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALEC Alector, Inc. R2K 2.16 - $239.81M - -69.73% - -46.00% -2.41%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4.75M7.11M6.50M-5.61M6.92M2.70M-7.17M3.17M5.90M4.11M6.57M182.41M24.47M79.85M14.85M16.55M56.21M9.11M15.89M15.08M15.34M3.67M7.87M3.26M6.24M1.05M
Cost of Revenue ----------------------------
Gross Profit ----------------------------
Operating Expenses -----------------------48.37M42.01M40.87M45.80M25.96M
Operating Income -9.22M-12.23M-16.82M-19.02M-20.76M-27.15M-34.15M-32.34M-42.08M-46.59M-53.75M-52.63M-55.33M126.33M-44.12M9.47M-47.75M-50.12M-3.59M-50.58M-43.71M-45.61M-48.43M-44.70M-34.14M-37.61M-39.57M-24.92M
EBITDA ------------------------42.85M-30.92M-35.28M-37.31M-22.84M
Interest Expense ----------------------------
Pretax Income ------------------------40.47M-30.52M-34.67M-37.10M-22.93M
Tax Provision -----------------------000168.00K0
Net Income -8.44M-11.12M-15.32M-17.37M-18.56M-24.56M-31.74M-30.53M-40.02M-45.33M-52.70M-52.17M-55.15M126.60M-44.62M9.88M-46.15M-45.86M1.38M-44.48M-36.08M-38.68M-42.22M-40.47M-30.52M-34.67M-37.27M-22.93M
Diluted EPS -----------0.67--0.691.49-0.540.12-0.56-0.550.02-0.53-0.38-0.40-0.43-0.41-0.30-0.34-0.34-0.21
R&D Expense 11.72M16.82M20.39M-20.61M25.64M28.52M-34.60M34.06M43.82M45.73M47.82M43.07M53.04M54.53M48.35M51.89M46.18M46.33M45.17M46.31M48.00M33.64M27.61M29.35M-17.86M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.87M27.51M21.22M21.10M207.09M133.62M97.06M100.56M21.05M
Cost of Revenue ---------
Gross Profit ---------
Operating Expenses -----271.45M248.80M245.56M177.05M
Operating Income -32.68M-57.29M-114.40M-195.17M-37.36M-137.83M-151.74M-145.00M-156.01M
EBITDA ------129.36M-142.89M-136.16M-146.35M
Interest Expense ---------
Pretax Income ------130.06M-125.18M-118.92M-142.76M
Tax Provision -----3.25M5.21M128.00K168.00K
Net Income -32.48M-52.25M-105.39M-190.23M-36.33M-133.31M-130.39M-119.05M-142.93M
Diluted EPS ----2.45-0.45-1.62-1.56-1.23-1.39
R&D Expense 29.91M73.03M100.53M156.87M189.41M210.42M192.12M185.94M123.06M

Compounded Sales Growth

5 Years:-46.00%
1 Year:-71.50%

Compounded Profit Growth

5 Years:-2.41%
1 Year:-

Stock Price Performance

1 Year:+62.41%
6 Months:+68.75%
3 Months:-11.11%
1 Month:-6.09%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --308.36M421.91M488.25M-787.65M621.83M468.30M293.24M
Current Assets ------726.43M565.81M424.82M266.45M
Cash & Equivalents -32.45M65.47M89.64M49.97M-154.32M74.56M33.02M65.80M
Inventory ----------
Receivables -----7.39M2.59M0--
Total Liabilities --195.24M227.17M220.72M-573.21M487.67M341.50M262.59M
Current Liabilities --47.95M61.97M68.09M-93.81M177.95M125.06M69.50M
Long Term Debt --------9.39M9.32M
Total Debt ------43.33M38.92M42.52M36.23M
Total Equity -24.91M-52.03M-97.40M194.74M267.53M-214.44M134.16M126.80M30.65M
Shares Outstanding ------82.90M84.88M99.09M110.36M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -17.77M127.46M-99.31M-166.73M--20.33M-184.16M-229.91M-184.03M
Investing Cash Flow -801.00K-224.12M-48.87M-105.05M--159.01M101.92M107.13M196.60M
Financing Cash Flow -15.00K131.15M172.35M232.11M-4.51M2.55M81.54M20.21M
Capital Expenditure -801.00K-1.88M-15.27M-5.03M--4.12M-2.38M-1.25M-41.00K
Free Cash Flow -18.57M125.58M-114.57M-171.77M--24.45M-186.54M-231.16M-184.07M
Net Change in Cash ------174.83M-79.69M-41.23M32.78M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------
Operating Margin % -1,137.8%-208.3%-539.2%-925.1%-18.0%-103.2%-156.3%-144.2%-741.3%
Net Margin % -1,130.9%-189.9%-496.7%-901.6%-17.5%-99.8%-134.3%-118.4%-679.2%
ROE % 62.4%53.6%-54.1%-71.1%--62.2%-97.2%-93.9%-466.3%
ROCE % --22.0%-31.8%-46.5%--19.9%-34.2%-42.2%-69.7%

Shareholding Pattern

Insiders
9.56%
Institutions
82.26%
Public Float
90.96%

Top Institutional Holders

#Holder% HeldSharesValue
1 TCG Crossover Management, LLC 9.01% 10.00M $21.60M
2 Blackrock Inc. 6.97% 7.74M $16.72M
3 Acadian Asset Management. LLC 3.64% 4.04M $8.72M
4 Foresite Capital Management IV, LLC 3.50% 3.89M $8.40M
5 Vanguard Capital Management LLC 3.31% 3.68M $7.95M
6 Merck & Co., Inc. 3.19% 3.55M $7.66M
7 Shaw D.E. & Co., Inc. 3.00% 3.33M $7.20M
8 683 Capital Management LLC 2.88% 3.20M $6.91M
9 Balyasny Asset Management LP 2.64% 2.94M $6.34M
10 Nantahala Capital Management, LLC 2.54% 2.82M $6.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALEC

Forbes Business Sun, 31 May 2026

Phillies’ Home Stadium Becomes Key In $10 Million Star’s Lawsuit With Parents

Philadelphia Phillies stadium Citizens Bank Park has emerged as an important venue for Alec Bohm’s ongoing legal battle with his parents.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space